About 15 million doses of Johnson & Johnson’s one-shot COVID-19 vaccine have been misplaced after a mix-up at a Baltimore manufacturing plant, the New York Instances reported Wednesday night time.
The plant, run by Emergent BioSolutions, is tasked with manufacturing two COVID-19 vaccines, the Instances reported. Employees on the plant conflated elements of the vaccines, ruining the doses, the newspaper reported.
Politico additionally reported senior officers instructed them that some senior Biden administration well being officers knew two weeks in the past that the Baltimore contractor’s manufacturing issues may delay supply of a big variety of future vaccine doses.
The combination-up doesn’t have an effect on Johnson & Johnson doses at the moment being delivered and used nationwide, since these have been developed within the Netherlands, in response to the Instances.
Johnson & Johnson recognized the spoiled batch of doses by means of its high quality management course of, the corporate mentioned in a press release on its web site. The positioning is “not but licensed to fabricate drug substance for our COVID-19 vaccine,” and added: “This batch was by no means superior to the filling and ending levels of our manufacturing course of.”
In its assertion, Johnson & Johnson mentioned it remained on monitor to ship “a further 24 million single-shot vaccine doses by means of April.” The drugmaker didn’t say what number of doses have been misplaced.
Additionally within the information:
►Most People 65 and older are totally vaccinated, in response to knowledge from the Facilities of Illness Management and Prevention.
►California Gov. Gavin Newsom will get vaccinated in Los Angeles Thursday morning, in response to his workplace.
►Individuals Journal reported Wednesday that former Alaska Gov. Sarah Palin says she examined optimistic for the coronavirus and is urging individuals to protect themselves within the pandemic, comparable to carrying masks in public.
►Washington state is opening eligibility for coronavirus vaccinations to all residents age 16 and older beginning April 15.
📈 As we speak’s numbers: The U.S. has over 30.45 million confirmed coronavirus circumstances and greater than 552,000 deaths, in response to Johns Hopkins College knowledge. The worldwide totals: 128.79 million circumstances and a pair of.81 million deaths. Greater than 195.58 million vaccine doses have been distributed within the U.S. and 150.2 million have been administered, in response to the CDC.
📘 What we’re studying: COVID-19 accounted for about 11% of all American deaths final yr – proper behind coronary heart illness and most cancers – and the overwhelming majority of sufferers who died of the virus already had well being issues earlier than they have been contaminated.
USA TODAY is monitoring COVID-19 information. Maintain refreshing this web page for the newest updates. Need extra? Join our Coronavirus Watch e-newsletter for updates to your inbox and be part of our Fb group.
FDA authorizes two speedy COVID-19 exams for house screening
Shoppers will quickly be capable of purchase speedy COVID-19 exams at chain pharmacies and grocers with out a prescription after the Meals and Drug Administration on Wednesday licensed two house exams.
The Abbott BinaxNOW COVID-19 self-test will embody two exams per package for serial screening, with the no-prescription check delivering ends in quarter-hour that doesn’t require a lab. The FDA additionally licensed the Quidel QuickVue COVID check that delivers ends in 10 minutes and can be utilized with out a prescription.
The FDA has licensed greater than 300 COVID-19 exams and applied sciences in what’s changing into an more and more crowded discipline of medical labs and tech corporations touting completely different applied sciences.
By greenlighting the Abbott and Quidel exams that may be bought by customers with out a prescription, the federal company is considerably increasing entry to testing for People. The authorization comes two weeks after the company introduced a streamlined path for serial testing to display screen individuals with out signs.
– Ken Alltucker
Pfizer-BioNTech COVID-19 vaccine proves protected and efficient for teenagers ages 12 to fifteen, firm examine reveals
The COVID-19 vaccine from drug firm Pfizer and its German accomplice BioNTech is protected for and intensely efficient in adolescents, in response to a company-sponsored examine launched early Wednesday.
In adolescents 12 to fifteen years outdated, vaccination led to a better protecting antibody response than in adults and was 100% efficient in opposition to symptomatic illness, the examine of two,260 adolescents discovered.
The 2-shot Pfizer-BioNTech vaccine had been licensed to be used in these 16 and up based mostly on earlier trials, however not in youthful adolescents.
Final week, the businesses started testing their vaccine in youngsters ages 5 to 11; subsequent week, they are going to start testing in ages 2 to five, and later they are going to have a look at youngsters 6 months to 2 years. Outcomes from these trials needs to be out there later this yr.
Moderna, which additionally has a COVID-19 vaccine, has been learning its shot in youngsters since December and launched a trial in youthful youngsters in mid-March. That vaccine just isn’t but accredited to be used in older teenagers.
Pfizer and BioNTech plan to submit their adolescent knowledge to the U.S. Meals and Drug Administration to ask that authorization to supply BNT162b2 be shortly amended to incorporate that age group. It isn’t clear how lengthy the FDA will take to overview the request.
– Karen Weintraub
Contributing: The Related Press